Our management team brings a wealth of experience from the biotech, pharmaceutical, human and animal health sectors – as well as first hand experience establishing, marketing and raising capital for a range of successful businesses in Australia, Asia and the US. What they all have in common is a shared belief in the future of the diagnostic testing market and a joint commitment to the ongoing success of Genetic Technologies.
Dr Paul Kasian, BSc, PhD, MBA, GAICD
Chief Executive Officer
Dr Kasian was appointed as acting Chief Executive Officer on February 6, 2018. Dr Kasian has held senior leadership positions in a number of investment groups and has significant funds management experience in Australia leading investment in the healthcare and life sciences sector. He holds a PhD in Microbiology and a Master of Business Administration, both from the University of Melbourne.
Paul Viney, FCPA, FGIA, FCIS, CFTP (Snr), MAICD, MInstD (NZ)
Chief Operating Officer, Chief Financial Officer and Company Secretary
Mr Viney was appointed to the role of Chief Operating Officer, Chief Financial Officer and Company Secretary on December 27, 2018. Paul was most recently Chief Executive Officer at ASX listed Powerhouse Ventures – a venture capital firm that invests in high technology in New Zealand and Australia. He has over 15 years experience in governance and strategic leadership of mid and small cap ASX listed entities, coupled with a strong mix of industrial (manufacturing) and med-tech company experiences and sound venture capital knowledge.
Richard Allman, PhD
Honorary Fellow, Centre for Epidemiology and Biostatistics The University of Melbourne
Chief Scientific Officer
Dr Allman brings over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Most recently he was responsible for providing scientific and technical guidance for the launch of the BREVAGen™ risk assessment test to the US market and managing both in-house research programs and external collaborative research projects, which include major academic units and commercial partners. Prior to entering the biotech sector, Dr Allman’s academic career encompassed oncology research, drug development, and assay design, with a particular interest in the linkage between onco-genetic profile and treatment response.